Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: A functional analysis

Blood

Volumn 111, Issue 1, 2008, Pages 183-189

  Boffa, Michael B ^a   Maret, Deborah ^a   Hamill, Jeffrey D ^a   Bastajian, Nazareth ^a   Crainich, Paul ^b   Jenny, Nancy S ^b   Tang, Zhonghua ^b   Macy, Elizabeth M ^b   Tracy, Russell P ^b   Franco, Rendrik F ^c   Nesheim, Michael E ^a,d   Koschinsky, Marlys L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c Fleury   (Brazil)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; MESSENGER RNA; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

3' UNTRANSLATED REGION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CPB2 GENE; DNA FLANKING REGION; FIBRINOLYSIS; GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RNA STABILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 38049153468     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-078543     Document Type: Article

References (49)

1. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26:2445-2453.
2. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
3. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
4. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B: modulation by glycosaminoglycans. J Biol Chem. 1999;274:35046-35052.
5. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176-27181.
6. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 1995;34:5811-5816.
7. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol. 2002;46:131-134.
8. Asai S, Sato T, Tada T, et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol. 2004;173:4669-4674.
9. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003;278:51059-51067.
10. Willemse JL, Hendriks DF. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge. Clin Chem. 2006;52:30-36.
11. Boffa MB, Koschinsky ML. Curiouser and curiouser: Recent advances in measurement of thrombin activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem. 2007;40:431-442.
12. Guimaraes AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol. 2004;124:659-665.
13. Frere C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost. 2005;94:373-379.
14. Guimaraes AH, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost. 2005;3:1284-1292.
15. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859.
16. Eichinger S, Schonauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103:3773-3776.
17. Libourel EJ, Bank I, Meinardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein (a) to the absolute risk of venous thromboembolism. Haematologica. 2002;87:1068-1073.
18. Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost. 2005;3:2211-2218.
19. Morange PE, Tregouet DA, Frere C, et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost. 2005;3:1503-1510.
20. Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364-368.
21. Zorio E, Castello R, Falco C, et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol. 2003;122:958-965.
22. Santamaria A, Martinez-Rubio A, Borrell M, et al. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica. 2004;89:880-881.
23. Morange PE, Juhan-Vague I, Scarabin PY, et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence: the PRIME Study (Prospective Epidemiological Study of MI). Thromb Haemost. 2003;89:554-560.
24. Brouwers GJ, Leebeek FW, Tanck MW, et al. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost. 2003;90:92-100.
25. Lau HK, Segev A, Hegele RA, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb Haemost. 2003;90:1187-1191.
26. Juhan-Vague I, Renucci JF, Grimaux M, et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156-2161.
27. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053-2058.
28. Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica. 2001;86:510-517.
29. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol. 2003;23:1122-1127.
30. Frere C, Tregouet DA, Morange PE, et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood. 2006;108:1562-1568.
31. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry. 1999;38:6547-6558.
32. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem. 1991;266:21833-21838.
33. National Center for Biotechnology Information. dbSNP database. http://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed August 28, 2007.
34. Maret D, Boffa MB, Brien DF, Nesheim ME, Koschinsky ML. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. J Thromb Haemost. 2004;2:1969-1679.
35. Wilson GM, Deeley RG. An episomal expression vector system for monitoring sequence-specific effects on mRNA stability in human cell lines. Plasmid. 1995;33:198-207.
36. Knowles BB, Howe CC, Aden DP. Abstract Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980;209:497-499.
37. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987;7:2745-2752.
38. Popperl H, Featherstone MS. Identification of a retinoic acid response element upstream of the murine Hox-4.2 gene. Mol Cell Biol. 1993;13:257-265.
39. Dani C, Piechaczyk M, Audigier Y, et al. Characterization of the transcription products of glyceraldehyde 3-phosphate-dehydrogenase gene in HeLa cells. Eur J Biochem. 1984;145:299-304.
40. Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord. 2001;1:59-74.
41. Boffa MB, Hamill JD, Maret D, et al. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem. 2003;278:9250-7.
42. Warren DM, Cole SA, Dyer TD, et al. A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans. Hum Biol. 2006;78:329-339.
43. Crainich P, Tang Z, Macy E, et al. A polymorphism at position -438 in the promoter region of thrombin-activatable fibrinolysis inhibitor is strongly associated with plasma antigen levels in healthy older men and women [abstract]. Circulation. 2000;102:866.
44. Garand M, Bastajian N, Nesheim ME, Boffa MB, Koschinsky ML. Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. Br J Haematol. 2007;138:231-244.
45. Ross J. mRNA stability in mammalian cells. Microbiol Rev. 1995;59:423-450.
46. Chen C-YA, Shyu A-B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995;20:465-470.
47. Shim J, Karin M. The control of mRNA stability in response to extracellular stimuli. Mol Cells. 2002;14:323-331.
48. Gahring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28:389-392.
49. Zhao J, Hyman L, Moore C. Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev. 1999;63:405-45.